Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update

Amornpun Wongkarnjana, Toyoshi Yanagihara, Martin R.J. Kolb

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Introduction: Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive and debilitating disease. Nintedanib is one of two anti-fibrotic therapies available for the treatment of IPF and has been approved since 2014. Together with pirfenidone and antacid medications it has received a conditional recommendation for the treatment for IPF by international clinical practice guidelines. Areas covered: The authors review the mechanisms of action, pharmacological profile and update scientific data and our opinions on efficacy, safety profile and tolerability of nintedanib. Expert opinion: Nintedanib significantly slows disease progression in IPF patients with tolerable and manageable side effects. Its potential future role in the treatment of progressive fibrosing interstitial lung diseases other than IPF is challenging.

Original languageEnglish
Pages (from-to)1139-1146
Number of pages8
JournalExpert Review of Respiratory Medicine
Issue number12
Publication statusPublished - Dec 2 2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update'. Together they form a unique fingerprint.

Cite this